Mvasi gets Canadian approval

Amgen has moved closer to introducing in Canada its Mvasi (bevacizumab) biosimilar rival to Genentech’s Avastin, after obtaining approval from Health Canada for 100mg/4ml and 400mg/16ml single-use vials. Stating that Mvasi’s indications were granted on the “basis of similarity” between the biosimilar and Avastin, a product monograph released by Health Canada noted that Mvasi will be used to treat metastatic colorectal cancer and locally advanced, metastatic or recurrent non-small cell lung cancer.

Amgen has moved closer to introducing in Canada its Mvasi (bevacizumab) biosimilar rival to Genentech’s Avastin, after obtaining approval from Health Canada for 100mg/4ml and 400mg/16ml single-use vials. Stating that Mvasi’s indications were granted on the “basis of similarity” between the biosimilar and Avastin, a product monograph released by Health Canada noted that Mvasi will be used to treat metastatic colorectal cancer and locally advanced, metastatic or recurrent non-small cell lung cancer.

At the start of the year, Amgen’s Mvasi was granted a pan-European marketing authorisation by the European Commission, representing the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin